BR112017009599A2 - composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal - Google Patents

composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal

Info

Publication number
BR112017009599A2
BR112017009599A2 BR112017009599A BR112017009599A BR112017009599A2 BR 112017009599 A2 BR112017009599 A2 BR 112017009599A2 BR 112017009599 A BR112017009599 A BR 112017009599A BR 112017009599 A BR112017009599 A BR 112017009599A BR 112017009599 A2 BR112017009599 A2 BR 112017009599A2
Authority
BR
Brazil
Prior art keywords
methods
apoaequorin
neuronal inflammation
containing compositions
individual
Prior art date
Application number
BR112017009599A
Other languages
English (en)
Inventor
R Moyer James Jr
Y Underwood Mark
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of BR112017009599A2 publication Critical patent/BR112017009599A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção está direcionada aos métodos de pré-condicionamento de neurônios para reduzir a inflamação neuronal em um indivíduo. tais métodos incluem uma etapa de administração de apoaequorina a um indivíduo, em que os neurônios do indivíduo são pré-condicionados para reduzir inflamação neuronal subsequente no indivíduo.
BR112017009599A 2014-11-11 2015-11-11 composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal BR112017009599A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078099P 2014-11-11 2014-11-11
PCT/US2015/060116 WO2016077437A1 (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation

Publications (1)

Publication Number Publication Date
BR112017009599A2 true BR112017009599A2 (pt) 2017-12-19

Family

ID=55954981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009599A BR112017009599A2 (pt) 2014-11-11 2015-11-11 composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal

Country Status (24)

Country Link
US (1) US20180214516A1 (pt)
EP (1) EP3217998B1 (pt)
JP (1) JP6861162B2 (pt)
KR (1) KR20170072350A (pt)
CN (1) CN107106649A (pt)
AU (2) AU2015346430B2 (pt)
BR (1) BR112017009599A2 (pt)
CA (1) CA2966891C (pt)
DK (1) DK3217998T3 (pt)
ES (1) ES2910021T3 (pt)
HK (2) HK1243343A1 (pt)
HR (1) HRP20220749T1 (pt)
HU (1) HUE059107T2 (pt)
IL (1) IL252070B (pt)
LT (1) LT3217998T (pt)
MA (1) MA40959A (pt)
MX (1) MX2017006063A (pt)
NZ (1) NZ731340A (pt)
PL (1) PL3217998T3 (pt)
PT (1) PT3217998T (pt)
RS (1) RS63269B1 (pt)
SG (2) SG11201703690XA (pt)
SI (1) SI3217998T1 (pt)
WO (1) WO2016077437A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190365854A1 (en) 2016-09-23 2019-12-05 Quincy Bioscience, Llc Apoaequorin and vitamin d-containing compositions and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ214563A (en) * 1984-12-31 1991-05-28 Univ Georgia Production of apoaeqorin using recombinant dna
MX2010009753A (es) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
US20110130336A1 (en) 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
MX350259B (es) * 2011-11-15 2017-08-31 Quincy Bioscience Llc Apoaequorina para reducir daño neuronal debido a isquemia.
US20150246101A1 (en) * 2012-09-27 2015-09-03 Mark Y. Underwood Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Also Published As

Publication number Publication date
HK1243343A1 (zh) 2018-07-13
IL252070B (en) 2022-06-01
ES2910021T3 (es) 2022-05-11
LT3217998T (lt) 2022-04-11
AU2015346430A1 (en) 2017-05-25
AU2015346430B2 (en) 2019-01-03
NZ731340A (en) 2018-11-30
HK1244223A1 (zh) 2018-08-03
PL3217998T3 (pl) 2022-07-11
US20180214516A1 (en) 2018-08-02
SG10202108723PA (en) 2021-09-29
DK3217998T3 (da) 2022-04-25
AU2018279057A1 (en) 2019-01-17
CA2966891A1 (en) 2016-05-19
PT3217998T (pt) 2022-04-05
EP3217998B1 (en) 2022-03-23
MA40959A (fr) 2017-09-19
IL252070A0 (en) 2017-07-31
RS63269B1 (sr) 2022-06-30
EP3217998A4 (en) 2018-06-27
MX2017006063A (es) 2017-07-27
WO2016077437A1 (en) 2016-05-19
SG11201703690XA (en) 2017-06-29
EP3217998A1 (en) 2017-09-20
JP6861162B2 (ja) 2021-04-21
CA2966891C (en) 2023-07-04
KR20170072350A (ko) 2017-06-26
HUE059107T2 (hu) 2022-10-28
CN107106649A (zh) 2017-08-29
HRP20220749T1 (hr) 2022-09-02
JP2017535607A (ja) 2017-11-30
SI3217998T1 (sl) 2022-07-29

Similar Documents

Publication Publication Date Title
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2019013657A (es) Metodo cosmetico para reducir las señales dermatologicas de envejecimiento.
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CR20160542A (es) 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
MX2021006734A (es) Metodo para tratar el cancer.
BR112015022942A2 (pt) heterociclos tricíclicos como inibidores da proteína bet
PH12019501763A1 (en) Method of reducing neutropenia
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
BR112016010166A2 (pt) métodos para usar interleucina-10 para tratar doenças e distúrbios
MX2018002344A (es) Metodo para tratar el cancer.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2019000149A1 (es) Composiciones y métodos para disminuir la expresión de tau, útiles para tratar enfermedades asociadas a tau. (divisional solicitud 201801652)
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017019971A2 (pt) exclusão de éxon induzida por anti-sentido em miostatina
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]